MarketInOut Stock Screener Log In | Sign Up
 

ImmunityBio Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
ImmunityBio Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,807.24 mln
Float401 mln
Earnings Date11/05/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-6.19
Highly reliable

Relative Strength

11 / 100
Significantly lagging

Pre-Tax Margin

-599%
Severely loss-making

ROE

135
Extraordinary

Altman Z-Score

-10.53
Deeply distressed

Business Description

ImmunityBio is a San Diego-based biotech company working to fight cancer and infectious diseases by developing treatments that strengthen the body's own immune system. Its most notable product, Anktiva, has received FDA approval for use in certain bladder cancer patients who have not responded to standard therapy. The company works across several treatment approaches, including proteins, vaccines, and cell-based therapies, and collaborates with leading research organizations such as the National Cancer Institute and partners in India and China.

Key Fundamentals

EPS-0.96
ROE135
RPS0.17
ROIC-113
ROA-184
Interest Cover-3.02
EBITDA, mln-861
EV / EBITDA-12.77
EV / EBIT-12.53
Revenue, mln166
EV / Revenue66.37

Quote Details

Last 8.22
Change -0.09 (-1.08%)
Open 8.21
Volume 5,920,782
Turnover 48,668,828
Average Volume 15,533,478

Financial Ratios

Pre-Tax Profit Margin-599
Current Ratio5.72
Price / Sales58.09

Financial Strength

Altman Z-Score-10.53
Piotroski F-Score 4 / 9
Beneish M-Score-6.19
Short Ratio11.29
Short % of Float30.95

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -10.46% 8 / 100   
1 Month -4.86% 41 / 100   
2 Months 9.6% 87 / 100   
6 Months 10.48% 83 / 100   
1 Year 248% 99 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog